Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 19;11(2):34.
doi: 10.3390/ph11020034.

Enhancing Whole Phage Therapy and Their Derived Antimicrobial Enzymes through Complex Formulation

Callum J Cooper  1 , Shazeeda Koonjan  2 , Anders S Nilsson  3
Affiliations
Review

Enhancing Whole Phage Therapy and Their Derived Antimicrobial Enzymes through Complex Formulation

Callum J Cooper et al. Pharmaceuticals (Basel). .

Abstract

The resurgence of research into phage biology and therapy is, in part, due to the increasing need for novel agents to treat multidrug-resistant infections. Despite a long clinical history in Eastern Europe and initial success within the food industry, commercialized phage products have yet to enter other sectors. This relative lack of success is, in part, due to the inherent biological limitations of whole phages. These include (but are not limited to) reaching target sites at sufficiently high concentrations to establish an infection which produces enough progeny phages to reduce the bacterial population in a clinically meaningful manner and the limited host range of some phages. Conversely, parallels can be drawn between antimicrobial enzymes derived from phages and conventional antibiotics. In the current article the biological limitations of whole phage-based therapeutics and their derived antimicrobial enzymes will be discussed. In addition, the ability of more complex formulations to address these issues, in the context of medical and non-medical applications, will also be included.

Keywords: bacteriophage; combination therapy; formulation; pharmacology; product development; synergy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Van Boeckel T.P., Gandra S., Ashok A., Caudron Q., Grenfell B.T., Levin S.A., Laxminarayan R. Global antibiotic consumption 2000 to 2010: An analysis of national pharmaceutical sales data. Lancet Infect. Dis. 2014;14:742–750. doi: 10.1016/S1473-3099(14)70780-7. - DOI - PubMed
    1. Van Boeckel T.P., Brower C., Gilbert M., Grenfell B.T., Levin S.A., Robinson T.P., Teillant A., Laxminarayan R. Global trends in antimicrobial use in food animals. Proc. Natl. Acad. Sci. USA. 2015;112:5649–5654. doi: 10.1073/pnas.1503141112. - DOI - PMC - PubMed
    1. Webber M.A., Whitehead R.N., Mount M., Loman N.J., Pallen M.J., Piddock L.J.V. Parallel evolutionary pathways to antibiotic resistance selected by biocide exposure. J. Antimicrob. Chemother. 2015;70:2241–2248. doi: 10.1093/jac/dkv109. - DOI - PMC - PubMed
    1. Soumet C., Méheust D., Pissavin C., Le Grandois P., Frémaux B., Feurer C., Le Roux A., Denis M., Maris P. Reduced susceptibilities to biocides and resistance to antibiotics in food-associated bacteria following exposure to quaternary ammonium compounds. J. Appl. Microbiol. 2016;121:1275–1281. doi: 10.1111/jam.13247. - DOI - PubMed
    1. Ng K.M., Ferreyra J.A., Higginbottom S.K., Lynch J.B., Kashyap P.C., Gopinath S., Naidu N., Choudhury B., Weimer B.C., Monack D.M., et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature. 2013;502:96–99. doi: 10.1038/nature12503. - DOI - PMC - PubMed

LinkOut - more resources